Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Consensus Target Price of $147.88

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $148.19.

Several research analysts have recently weighed in on MIRM shares. Evercore restated an “outperform” rating and set a $146.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, October 13th. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. TD Cowen increased their price target on Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price target on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Finally, Stifel Nicolaus lifted their price objective on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $80.39 on Wednesday. Mirum Pharmaceuticals has a twelve month low of $63.23 and a twelve month high of $130.00. The company’s 50-day moving average price is $91.43 and its 200-day moving average price is $100.29. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same period in the prior year, the company posted ($0.12) EPS. The firm’s revenue was up 37.9% on a year-over-year basis. On average, research analysts expect that Mirum Pharmaceuticals will post -1.32 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the sale, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at $19,187,339.20. This trade represents a 13.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the sale, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,499 shares of company stock worth $9,797,834 in the last three months. 8.32% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new position in Mirum Pharmaceuticals in the 2nd quarter valued at about $27,000. Summit Securities Group LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at approximately $42,000. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $44,000. State of Wyoming acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $52,000. Finally, Fifth Third Bancorp acquired a new stake in shares of Mirum Pharmaceuticals during the 1st quarter worth approximately $56,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.